Back to Directory Rachael Jeffrey Email rjeffrey@fhi360.org Phone (919) 321-3779 Institution FHI 360 Title Clinical Research Manager Address FHI360 359 Blackwell St Durham, NC 27701 Request an Update Affiliated Studies IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Complications & Comorbidities Study Status Open to Accrual IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Complications & Comorbidities Study Status Open to Accrual
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling